Bay Street News

Bay Street News, January 13th, 2019

Home / 2019 / January / 13
  0
NASDAQ Companies - January 13, 2019

ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer

SINGAPORE, Jan. 14, 2019 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both […]

Read More
  0
NASDAQ Companies - January 13, 2019

Manhattan Associates Elevates In-Store Customer Service with Expanded Customer Engagement Solution

New Enhancements Give Store Associates the Tools They Need to Deliver a Consistently Outstanding Customer Experience NEW YORK, Jan. 13, […]

Read More
Load More
Navigation
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Latest News
  • Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis
  • Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
  • Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
  • DMG Blockchain Solutions Inc. Announces Filing of Prospectus Supplement in Respect of $15,004,300 Unit Offering
  • HPH Files Annual Report on Form 20-F on November 15, 2024

Tweets by baystnews

© 2020 BayStNews.com - All Rights Reserved
  • Home
  • TSX News
  • TSX Venture News
  • NASDAQ Companies
  • NYSE Companies
  • Canadian Stock Exchange News
  • Pink Sheets News
  • OTCBB News
Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search